An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma

Journal of the National Cancer Institute

Volumn 105, Issue 24, 2013, Pages 1862-1870

  Hakimi, A Ari ^a,b   Furberg, Helena ^c   Zabor, Emily C ^c   Jacobsen, Anders ^d   Schultz, Nikolaus ^d   Ciriello, Giovanni ^d   Mikklineni, Nina ^a   Fiegoli, Brandon ^a   Kim, Philip H ^a   Voss, Martin H ^c   Shen, Hui ^d   Laird, Peter W ^a,e   Sander, Chris ^d   Reuter, Victor E ^c   Motzer, Robert J ^c,f   Hsieh, James J ^a,b,c,e,f   Russo, Paul ^a,f  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Human Oncology and Pathogenesis Program   (United States)

^c Epidemiology and Biostatistics ^*  (United States)

^d Computational Biology ^*  (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; FATTY ACID; FATTY ACID SYNTHASE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CANCER CENTER; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PATIENT; CANCER SPECIFIC MORTALITY; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA METHYLATION; FEMALE; FISHER EXACT TEST; GENE DOSAGE; GENE EXPRESSION; GENOMICS; HAZARD RATIO; HUMAN; KIDNEY CARCINOMA; KIDNEY SURGERY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; NUTRITIONAL STATUS; OBESITY; PRIORITY JOURNAL; RISK FACTOR; SOMATIC MUTATION; TUMOR GENE; TUMOR VOLUME;

EID: 84891444793     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt310     Document Type: Article

References (35)

1. Hollingsworth JM, Miller DC, Daignault S, et al. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98(18):1331-1334.
2. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569-578.
3. Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med. 2010;61:301-316.
4. Vucenik I, Stains JP. Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann N Y Acad Sci. 2012;1271:37-43.
5. Klinghoffer Z, Yang B, Kapoor A, et al. Obesity and renal cell carcinoma: epidemiology, underlying mechanisms and management considerations. Expert Rev Anticancer Ther. 2009;9(7):975-987.
6. Choi Y, Park B, Jeong BC, et al. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int J Cancer. 2013;132(3):625-634.
7. Kovesdy CP, Anderson JE. Reverse epidemiology in patients with chronic kidney disease who are not yet on dialysis. Semin Dial. 2007;20(6):566-569.
8. Oreopoulos A, Padwal R, Kalantar-Zadeh K, et al. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J. 2008;156(1):13-22.
9. Uretsky S, Messerli FH, Bangalore S, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med. 2007;120(10):863-870.
10. Romero-Corral A, Montori VM, Somers VK, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006;368(9536):666-678.
11. Carnethon MR, De Chavez PJ, Biggs ML, et al. Association of weight status with mortality in adults with incident diabetes. JAMA. 2012;308(6):581-590.
12. Kalantar-Zadeh K, Streja E, Kovesdy CP, et al. The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc. 2010;85(11):991-1001.
13. Parekh N, Chandran U, Bandera EV. Obesity in cancer survival. Annu Rev Nutr. 2012;32:311-342.
14. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307(5):491-497.
15. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27(5):612-624.
16. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002.
17. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253.
18. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
19. Baker JP, Detsky AS, Wesson DE, et al. Nutritional assessment: a comparison of clinical judgement and objective measurements. N Engl J Med. 1982;306(16):969-972.
20. Gibbs J, Cull W, Henderson W, et al. Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. Arch Surg. 1999;134(1):36-42.
21. Mermel CH, Schumacher SE, Hill B, et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.
22. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
23. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550.
24. Horiguchi A, Asano T, Asano T, et al. Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma. J Urol. 2008;180(3):1137-1140.
25. Ogino S, Nosho K, Meyerhardt JA, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol. 2008;26(35):5713-5720.
26. Nguyen PL, Ma J, Chavarro JE, et al. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol. 2010;28(25):3958-3964.
27. Johnson EF, Palmer CN, Griffin KJ, et al. Role of the peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation. FASEB J. 1996;10(11):1241-1248.
28. Smits KM, Schouten LJ, Hudak E, et al. Body mass index and von Hippel-Lindau gene mutations in clear-cell renal cancer: results of the Netherlands Cohort Study on diet and cancer. Ann Epidemiol. 2010;20(5):401-404.
29. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763-777.
30. Horiguchi A, Asano T, Asano T, et al. Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells. J Urol. 2008;180(2):729-736.
31. Kuchiba A, Morikawa T, Yamauchi M, et al. Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses' health study. J Natl Cancer Inst. 2012;104(5):415-420.
32. Choi JW, Song JS, Pai SH. Associations of serum TRAIL concentrations, anthropometric variables, and serum lipid parameters in healthy adults. Ann Clin Lab Sci. 2004;34(4):400-404.
33. Keuper M, Wernstedt Asterholm I, Scherer PE, et al. TRAIL (TNFrelated apoptosis-inducing ligand) regulates adipocyte metabolism by caspase-mediated cleavage of PPARgamma. Cell Death Dis. 2013;4:e474.
34. Florez H, Castillo-Florez S. Beyond the obesity paradox in diabetes: fitness, fatness, and mortality. JAMA. 2012;308(6):619-620.
35. Berrington de Gonzalez A, Morton LM. Converting epidemiologic studies of cancer etiology to survivorship studies: approaches and challenges. Cancer Epidemiol Biomarkers Prev. 2012;21(6):875-880.